Invention Application
- Patent Title: CORONAVIRUS VACCINE
-
Application No.: PCT/US2021/042692Application Date: 2021-07-22
-
Publication No.: WO2022020545A2Publication Date: 2022-01-27
- Inventor: GILL, Harvinder, Singh , JOSHI, Gaurav
- Applicant: TEXAS TECH UNIVERSITY SYSTEM
- Applicant Address: Office of Research Commercialization
- Assignee: TEXAS TECH UNIVERSITY SYSTEM
- Current Assignee: TEXAS TECH UNIVERSITY SYSTEM
- Current Assignee Address: Office of Research Commercialization
- Agency: CHALKER, Daniel, J. et al.
- Priority: US63/054,938 2020-07-22
- Main IPC: A61K39/12
- IPC: A61K39/12 ; A61K39/215 ; A61P31/14 ; C12N15/63 ; C12N7/01 ; A61K2039/55555 ; A61K2039/55561 ; A61K2039/575 ; A61K2039/58 ; A61K2039/70 ; C07K14/00 ; C12N2770/20034
Abstract:
The present invention includes and immunogenic composition and methods of immunizing a mammal or avian comprising: a nanoparticle conjugated to one or more antigenic peptides or fusion polypeptides from more than one strain of virus, wherein the one or more antigenic peptides or fusion polypeptides elicit at least one of a humoral, T helper cell-1 (Th1), T helper cell-2 (Th2) or cytotoxic T cell (CTL) immune response. In certain embodiments the antigenic peptides or fusion polypeptides are selected from at least one of SEQ IN NOS: 1 to 16, 22 to 39, or any combination thereof.
Information query